Given the ongoing efforts to develop increasingly improved mouse models mimicking particular human tumors, such as the widely used MMTV-erbB2 transgenics for breast cancer, the present mouse model constitutes a versatile preclinical model to assess possible synergies between TRAIL-based therapeutics, such as recombinant TRAIL derivatives, TRAIL mimics or agonistic TRAIL receptor antibodies, and other cancer therapeutics in a organ and tumor type-specific manner. The gene discussed is TNFSF10; the disease is breast cancer.